Response by baseline BCR-ABL mutation analysis of patients with CML in MBC
| . | No. patients (%) at 8-mo follow-up . | ||
|---|---|---|---|
| Total . | MaHR . | MCyR . | |
| No mutation | 40 (57) | 15/40 (38) | 15/40 (38) |
| Any mutation | 30 (43) | 10/30 (33) | 8/30 (27) |
| P-loop | 18 (26) | 6/18 (33) | 5/18 (28) |
| Activation loop | 5 (7) | 1/5 (20) | 0/5 (0) |
| Other regions | 9 (13) | 3/9 (33) | 3/9 (33) |
| M244V* | 3 | 1 | 1 |
| G250E* | 6 | 1 | 0 |
| Y253H* | 5 | 3 | 3 |
| E255K* | 2 | 0 | 0 |
| T315I* | 4 | 0 | 0 |
| L324Q* | 2 | 2 | 1 |
| H396R* | 4 | 1 | 0 |
| F486S* | 2 | 0 | 0 |
| . | No. patients (%) at 8-mo follow-up . | ||
|---|---|---|---|
| Total . | MaHR . | MCyR . | |
| No mutation | 40 (57) | 15/40 (38) | 15/40 (38) |
| Any mutation | 30 (43) | 10/30 (33) | 8/30 (27) |
| P-loop | 18 (26) | 6/18 (33) | 5/18 (28) |
| Activation loop | 5 (7) | 1/5 (20) | 0/5 (0) |
| Other regions | 9 (13) | 3/9 (33) | 3/9 (33) |
| M244V* | 3 | 1 | 1 |
| G250E* | 6 | 1 | 0 |
| Y253H* | 5 | 3 | 3 |
| E255K* | 2 | 0 | 0 |
| T315I* | 4 | 0 | 0 |
| L324Q* | 2 | 2 | 1 |
| H396R* | 4 | 1 | 0 |
| F486S* | 2 | 0 | 0 |
Mutational analysis was not performed at baseline for 4 of 74 patients. P-loop mutations are those in locations 244 through 255.
Activation loop mutations are those in locations 379 through 398. N = 70.
Mutations documented in at least 2 patients.